Lawmakers want FDA to boot phthalates

Share this article:

Members of the House Energy and Commerce Committee are asking FDA Commissioner Margaret Hamburg to assess the agency's authority to regulate phthalates and get the chemicals out of US pharmaceuticals.

Regulatory Focus reports that the FDA's Center for Drug Evaluation and Research said back in 2012 that it wanted to reduce the use of some phthalates in pharmaceuticals because animal studies showed an association between exposure and reproductive toxicity. (There's also been lobbying to get them out of US cosmetics.)

Representatives Henry Waxman (D-CA), Frank Pallone Jr. (D-NJ) and Jan Schakowsky (D-IL) are urging action now, based on a report by the Consumer Product Commission's Chronic Hazard Panel on Phthalates which said phthalates are a significant risk to human health.

The writers called the report alarming, and ask the FDA to act well before the 180-day period window provided by the consumer commission.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.